Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2018-09-18 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Investor Symposium
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is providing 'Additional information' via RNS, which is the news service of the London Stock Exchange. The content announces an 'Investor Symposium' and notes that presentations from the event 'will be made available on the Company website'. This structure—a brief announcement about an upcoming event where materials will be released later—fits the definition of a Report Publication Announcement (RPA), as it is announcing the future availability of presentations/information rather than being the full report itself. Since RPA is a specific category, it takes precedence over the general RNS fallback, although the source is RNS.
2018-09-18 English
Notice of Investor Symposium
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and contains a date stamp typical of regulatory news services. The content announces an 'Investor Symposium' where the CEO and experts will present on the company's drug candidate (SFX-01) and clinical trials. This is an announcement intended for investors and analysts regarding a future event, not the release of a full financial report (like 10-K or IR) or the results themselves (ER). Since it is a formal announcement distributed via RNS, and it doesn't fit neatly into specific categories like DIV, DIRS, or MANG, it falls under the general regulatory announcement category, RNS, or potentially Investor Presentation (IP) if it were the presentation itself. However, since this is the *notice* of the event, RNS is the most appropriate classification for this type of regulatory news release.
2018-09-11 English
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
Regulatory Filings Classification · 1% confidence The document is a press release dated August 1, 2018, announcing the initiation of a Phase 2 clinical trial for a drug candidate (RPL554) and providing an update on expected top-line data timing (Q1 2019). It details the trial design, background on the disease (COPD), and includes forward-looking statements referencing the need for data to inform Phase 3 trials. This content structure—a news announcement about clinical trial progress and future expectations—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific operational update rather than a summary of overall financial performance (ER) or a mandatory regulatory form, and it is a formal announcement distributed via GlobeNewswire, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release if it were tied to a specific reporting period, but the focus here is clinical development news. Given the options, and the nature of this being a company update distributed broadly, RNS is the most appropriate general category for non-standard, time-sensitive operational news, although ER is also plausible if this was released around an earnings cycle. However, since it is primarily a clinical trial update, RNS serves as the best fit among the provided specific codes for general corporate news not covered elsewhere.
2018-08-01 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document text is very short (1494 characters) and contains the RNS Number '1653W' and mentions 'N4 Pharma PLC' and the date '30 July 2018'. The content discusses a 'Second Price Monitoring Extension' related to trading activity, which is a specific market operational announcement. It explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates a general regulatory announcement that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a direct, short regulatory notice provided via the RNS system, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement category.
2018-07-30 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1477 characters) and contains an 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange'. The content itself is a 'Price Monitoring Extension' notice regarding an auction call extension, which is a specific, non-standard regulatory market announcement. Since it is a direct, short announcement disseminated via the RNS system and does not fit into specific financial reporting categories (like 10-K, ER, IR), it falls best under the general regulatory announcement category.
2018-07-30 English
Result of AGM
AGM Information Classification · 1% confidence The document explicitly states 'Results of AGM' and confirms that 'all resolutions were duly passed at its Annual General Meeting ("AGM") held earlier today.' This directly relates to the outcomes of the Annual General Meeting. The presence of an RNS Number and the general format suggest a regulatory announcement, but the specific content points to the results of the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). It is not a DVA (Declaration of Voting Results) because DVA is defined as 'Official results from shareholder votes at any general meeting,' which is very similar, but AGM-R is specifically for 'Presentations and materials shared during the Annual General Meeting (AGM).' Since this document confirms the passing of resolutions at the AGM, AGM-R is the best fit, although DVA is a close secondary possibility. Given the context of confirming the meeting's outcome, AGM-R is chosen.
2018-07-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.